| Description | FGFR1 inhibitor-2 (with an IC50 of 4.55 μM in MDA-MB-231 cells) is a potent inhibitor of FGFR1. It is specifically useful for studying metastatic triple-negative breast cancer. |
| In vitro | FGFR1 inhibitor-2 (3 and 6 μM; 48 hours; MDA-MB-231) reduces the expression of FGFR1[1]. FGFR1 inhibitor-2 (0~5 μM; MDA-MB-231) increases the apoptotic index by 10.6-fold at 5 μM[1]. Western Blot Analysis[1]Cell Line: MDA-MB-231 Concentration: 3 and 6 μM Incubation Time: 48 hours Result: Reduced the expression of FGFR1. |
| Synonyms | FGFR1 inhibitor-2 |
| molecular weight | 507.461 |
| Molecular formula | C25H22F5N3O3 |
| CAS | 2410612-08-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Ashraf-Uz-Zaman M, et al. Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer. Eur J Med Chem. 2021;209:112866. |